amudu

Thursday, June 9, 2011

WASHINGTON, DC – At a time when the global economy is suffering from a crisis of confidence, structural imbalances, and subdued growth prospects, looking ahead ten years to predict the course of development requires careful modeling and something beyond sagacity. What is needed is a multifaceted approach that combines a sense of history with careful analysis of current forces such as the shift in the balance of global growth toward the emerging world.

Such forecasting also requires an understanding of how advanced economies are coming to grips with that shift, and how the international monetary system will adjust as a result. Having studied these factors, we believe that the world economy is on the verge of a transformative change – the transition to a multipolar world economic order.

Throughout history, paradigms of economic power have been drawn and redrawn according to the rise and fall of those countries best equipped to drive global growth and provide stimulus to the global economy. Multipolarity, meaning more than two dominant growth poles, has at times been a key feature of the world economy. But at no time in modern history have developing countries been at the forefront of a multipolar economic system.

This pattern is set to change. By 2025, six emerging economies – Brazil, China, India, Indonesia, South Korea, and Russia – will collectively account for about one-half of global growth. The international monetary system is likely to cease being dominated by a single currency over the same years. As they pursue growth opportunities abroad and are encouraged by improved polices at home, emerging-market corporations will play an increasingly prominent role in global business and cross-border investment, while large pools of capital within their borders will allow emerging economies to become key players in financial markets.

As dynamic emerging economies evolve to take their place at the helm of the world economy, a rethink of the conventional approach to global economic governance is needed. The current approach rests on three premises: the link between concentrated economic power and stability; the North-South axis of capital flows; and the centrality of the US dollar.

Since the end of World War II, the US-centered global economic order has been built on a complementary set of tacit economic and security arrangements between the United States and its core partners, with emerging economies playing a peripheral role. In exchange for the US assuming the responsibilities of system maintenance, serving as market of last resort, and accepting the international role of the dollar, its key economic partners, Western Europe and Japan, acquiesced in the special privileges enjoyed by the US – seigniorage gains, domestic macroeconomic-policy autonomy, and balance-of-payments flexibility.

Broadly, this arrangement still holds today, though hints of its erosion became evident some time ago. The benefits that emerging economies have reaped from expanding their presence in international trade and finance are but one example of this.

An increasingly multipolar global economy is likely to change the way the world conducts international business. A number of dynamic emerging-market firms are on a path toward dominating their industrial sectors globally in the coming years – much in the same way that companies based in advanced economies have done for the past half-century. In the years ahead, such firms are likely to press for economic reforms at home, serving as a force for increased integration of their home countries into global trade and finance.

So the time may be ripe to move forward with the sort of multilateral framework for regulating cross-border investment that has been derailed several times since the 1920’s. In contrast to international trade and monetary relations, no multilateral regime exists to promote and govern cross-border investment.

For now, the US dollar remains the most important international currency. But this dominance is waning, as evidenced by its declining use as an official reserve currency, as well as for invoicing goods and services, denominating international claims, and anchoring exchange rates.

The euro represents the dollar’s strongest competitor, so long as the eurozone successfully addresses its current sovereign-debt crisis through bailouts and longer-term institutional reforms that safeguard the gains from a long-running single-market project. But developing countries’ currencies will undoubtedly become more prominent in the longer term.

The size and dynamism of China’s economy, and the rapid globalization of its corporations and banks, makes the renminbi especially likely to take on a more important international role. In Global Development Horizons 2011, the World Bank presents what it believes to be the most probable global currency scenario in 2025 – a multicurrency arrangement centered on the dollar, euro, and renminbi. This scenario is buttressed by the likelihood that the US, the eurozone, and China will constitute the three major growth poles at that time.

Finally, the international financial community must live up to its responsibility to ensure that the development agenda remains a priority. Countries with global economic clout have a special responsibility to accept that their policy actions have important spillover effects on other countries. Monetary-policy initiatives that emphasize increased collaboration among central banks to achieve financial stability and sustainable growth in global liquidity thus would be particularly welcome.

Despite the considerable progress that developing countries have made in integrating themselves into international trade and finance channels, there is still much work to be done to ensure that they share the burden of maintaining the global system in which they have a rapidly growing stake. At the same time, it is critical that major developed countries craft policies that take into account their growing interdependency with developing countries. More and more, global governance will depend on leveraging that interdependency to strengthen international cooperation and boost worldwide prosperity.

Justin Yifu Lin is Chief Economist of the World Bank. Mansoor Dailami is lead author of Global Development Horizons, and Manager of the Emerging Global Trends Team of the Development Prospects Group at the World Bank.

Hormone spray boosts memory

MONASH UNIVERSITY

“...women have far less testosterone and double the rate of dementia, hence the thought that maybe testosterone protects memory.”

Image: suesmith2/iStockphoto

A new Monash study has revealed testosterone spray improves memory in menopausal women.

Dr Sonia Davison from Monash University’s Women’s Health program led the study and said the results could form the basis of a new therapy to slow cognitive decline and reduce dementia in women.

“Memory loss is one of the warning signs of dementia,” Dr Davison said.

“As women age their testosterone levels decrease, reaching a low at age 65, which also happens to be the age at which dementia incidence begins to climb.”

“Compared to men, women have far less testosterone and double the rate of dementia, hence the thought that maybe testosterone protects memory.”

“This study investigated whether restoring women to their youthful testosterone levels would improve memory, as finding a way to reduce the onset of dementia could impact the lives of countless women worldwide.”

The study compared a control group of 30 women, who received no treatment, with a group of nine women in early menopause (ages 47 to 60) who received the testosterone spray on their skin.

The spray dose returned testosterone levels to those typical of young women of childbearing age.

After 26 weeks the testosterone-treated group had significantly improved their verbal learning and memory, while the control group showed no significant change.

“What is exciting is that the testosterone-treated women were all healthy, with no cognitive impairment, and there was still a definite treatment effect from the spray,” Dr Davison said.

Dr Davison is now recruiting larger numbers of women aged 55-70 to participate in follow-up studies that will trial a testosterone gel and a testosterone patch.

Women in Australia who are interested in participating should contact Monash University’s Women’s Health Program on 03 9903 0827.

An abstract from Dr Davison’s study was presented this morning as part of The Endocrine Society’s 93rd Annual Meeting in Boston, USA. The abstract was also selected for inclusion in the Society’s Research Summaries Book, which aims to promote exciting research to the public.

Who owns the rights to the human body? It’s patently obvious

LUIGI PALOMBI

Read the argument against the proposed legislation

Patents are only to be for granted inventions – that’s the intent of the Patents Act 1990, it has been the law for nearly 400 years, and it’s also what Article 27.1 of TRIPS says in black and white.

About 30 years ago, a new patent office practice was established by the United States Patent and Trademark Office, the European Patent Office and the Japan Patent Office.

The change essentially meant that naturally occurring biological materials, such as DNA and amino acids or proteins, which have been isolated (removed from their natural environment), could be considered to be inventions.

This practice was subsequently adopted in Australia and its implementation resulted in the granting of thousands of patents over isolated biological materials from a variety of sources, including viruses, bacteria, human genome and plant genomes.

However, the legality of this practice was never tested, either in a United States or Australian court – until 2009 in the former and 2010 in Australia.

This only happened when the legality of patents granted to Myriad Genetics over the BRCA 1 and BRCA 2 genes and their use in genetic tests were challenged.

In the United States, a Federal Court judge held in March 2010 that the US patents, insofar as they claimed the BRCA 1 and BRCA 2 genes as inventions, were invalid.

The judge held that the isolation of a naturally occurring biological material was not the equivalent of transforming that material from a product of nature into a product of humankind.

His decision has been appealed and the appeal was heard a few weeks ago. You can listen to the legal arguments here.

Whatever the outcome of that appeal, it is likely that the case will go to the US Supreme Court for final determination.

In Australia, a test case is proceeding through the Federal Court and a tentative trial date has been set for September 2011, but there is a strong possibility that that date will change.

Patent Amendment (Human Genes and Biological Materials) Bill 2010

The Patent Amendment Bill going through the Australian Parliament seeks to define what an invention is in the context of biological materials which are (and this next bit is important) identical or substantially identical to what exists in nature.

In other words, it seeks to close the loophole which the US patent office practice opened 30 years ago.

The intent of the Bill is to make it clear that a naturally occurring biological material isolated from its natural environment is not patentable matter, that is, it is not an invention.

This is a scientific fact. As an example, imagine a cotton ball – removing a cotton ball from a cotton plant doesn’t make the cotton ball an invention. It is absurd to suggest it does.

The Bill does not prevent the patenting of modified biological materials if they are substantially different to those that exist in nature.

So, the modified protein which is at the heart of the Gardasil vaccine would not be affected. Neither would the monoclonal antibody which is at the heart of Herceptin, nor the modified human insulin which is at the heart of NovoLog.

These are biological materials but each have been modified so they function in a way that unmodified proteins do not and their enhanced function is sufficient to distinguish them from their naturally occurring parent proteins.

Further, the Bill does not prevent the patenting of vaccines, medicines, diagnostics and therapeutics that use biological materials as their active ingredient.

So, even if the Bill becomes the law, it will still be possible to apply for a patent for a vaccine containing a biological material identical to one existing in nature, such as a vaccine using a live attenuated viral strain.

All the Bill does is prevent the patenting of the naturally occurring biological material itself, not the product which uses such a material to produce a new and inventive efficacious result, which is what a new vaccine does.

Ultimately, the Bill merely applies patent law as it was always intended to be applied.

Even the US government acknowledges the USPTO’s practice was wrong in law. In October 2010, the US Department of Justice, on behalf of the US government, filed an amicus (friend of the court) brief in the Myriad BRCA US patent appeal.

The brief said that having reviewed the “longstanding practice of the [U.S.] Patent and Trademark Office” relating to “patents for isolated genomic DNA”, the Department of Justice found the practice to be contrary to “settled principle under [U.S.] Supreme Court precedent”.

The main reason for the opposition to the Bill is that it will achieve its stated aim.

Those who oppose it have either obtained patents on isolated biological materials which are identical or substantially similar to those that exist in nature (pharmaceutical and biotechnology companies, universities and certain research institutions) or have participated in procuring such patents (patent attorneys and intellectual property lawyers) or are financially benefiting from them.

Their opposition is an over reaction because the Bill will not actually stop the patenting of new and inventive diagnostics, medicines and therapeutics which contain or incorporate these biological materials.

It will merely prevent the patenting of the biological materials existing in nature or those derived from such materials that function in exactly the same way.

The argument that this Bill will bring the Australian biotechnology sector to its knees is complete and utter nonsense.

It is regrettable that some of Australia’s leading scientists have publicly opposed it when all it seeks to do is ensure that only true inventions are rewarded with a patent monopoly.

What did you miss

What did you miss

A planet going the wrong way

THE AUSTRALIAN NATIONAL UNIVERSITY

"Until now it has been assumed that any planets orbiting a star would be moving in the same direction as the star’s spin."

Image: akirastock/iStockphoto

All planets move around their stars in the same direction as the star spins—at least that’s what we thought. But now ANU astronomer Dr Daniel Bayliss and his colleagues have found a planet that breaks the mould.

Dr Bayliss, from the Research School of Astronomy and Astrophysics, is one of 16 early-career scientists unveiling their research to the public at Fresh Science – a national program sponsored by the Australian Government.

Using one of the world’s largest telescopes in Chile, Daniel and his collaborators discovered that a distant planet WASP-17b is moving in the opposite direction to the spin of the star around which it orbits. The discovery throws traditional theories about how planets form around stars into doubt.

Planets form from the same disk of rotating material that gives birth to the star around which they move. So until now it has been assumed that any planets orbiting a star would be moving in the same direction as the star’s spin. This is certainly true in our own Solar System.

WASP-17b is quite different, Dr Bayliss says, and its backwards motion is somewhat of a mystery to scientists.

“It is possible that the planet underwent a close encounter with another giant planet billions of years ago, which altered its orbit so much that it began orbiting backwards,” he said.

It is not known what fraction of planets orbit their stars in this retrograde manner, but astronomers are now actively trying to monitor other distant planets to see how common it is. If it were common, this would not bode well for the chances of life around other stars. Close encounters between giant planets would most probably destroy any small Earth-like planet in that system, and wipe out any chance of life arising.

At present, only a handful of distant planets are known, but Dr Bayliss is part of a project, called HAT-South, which is monitoring millions of stars in the southern hemisphere to see if they have orbiting planets. As part of this program, he runs a set of telescopes in Australia, the data from which is combined with those of identical sets of telescopes operated in Chile and Namibia.

This global enterprise should uncover dozens of new planets, providing the necessary information on how common backwards movement is in our Galaxy.

‘Lefties’ more gifted ‘a myth’

FLINDERS UNIVERSITY

Left-handed people consistently perform worse than right-handed people in measures of cognitive ability, or IQ, with the ‘level of disability’ equivalent to being prematurely born.

This is the finding of a recent study led by Professor Mike Nicholls (pictured), newly-appointed Director of the Brain and Cognition Laboratory in Flinders University’s School of Psychology, which dispels the common myth that left-handed people are more likely to be gifted.

“The evidence, based on our analyses of very large databases of handedness and other attributes in people across Australia, the UK and the USA, doesn’t bear out that myth,” Professor Nicholls said.

“Our study of members of the same family confirms that left-handed children will do worse than their right-handed siblings,” he said.

Professor Nicholls, who is himself left-handed, has been appointed to one of the new Strategic Professorships designed to bolster specific areas of research.

He joined Flinders in January after 17 years at the University of Melbourne.

Over that time, he was awarded seven large Australian Research Council grants for projects examining how the brain affects behaviour.

He said handedness is tied to left/right asymmetries in the brain, or laterality – a major research focus of the Laboratory.

“Left and right could so easily be the same in humans and in some animal species it is the same. In humans, though, there seems to be this large specialisation of the two sides of the brain,” he said.

“It is most likely related to squeezing as many eggs as possible into one basket.”

Spatial attention is the second research focus of the Laboratory team which includes postdoctoral fellows Tobias Loetscher from Switzerland and Nicole Thomas from Canada.

“We’re very interested in how the general population tends to pay more attention to the left-hand side of an object than the right,” Professor Nicholls said.

This bias manifests itself as a tendency to deviate to the right in activities from steering a wheelchair to walking and even goal-kicking.

“There is a difference between near and far space and how the brain codes what can and cannot be touched.

“In the case of AFL footballers, when they aim for the midpoint between two posts, they tend to kick slightly to the right of middle.”

Professor Nicholls said the ultimate goal of his research is to develop remedial techniques for people with neurological problems such as ADHD and brain damage.

Tamarind seeds regrow nerves

MONASH UNIVERSITY

A Monash University researcher has developed a new biomaterial that encourages damaged nerves in the brain and spinal chord to regrow. The work could revolutionise treatment of nerve-based injuries and diseases, such as Parkinson’s.

PhD student Andrew Rodda was part of a Monash Materials Engineering team investigating xyloglucan, a plant-based compound derived from the seeds of the tamarind tree.

Within plants, xyloglucan plays an important role in linking cells together and Mr Rodda has been studying its effects in animals with damaged nerve cells.

The compound developed by Mr Rodda can be injected into an injury site as a liquid, before becoming a gel as it reaches body temperature.

Once in place, the gel acts as a support structure through which healthy cells can migrate and potentially reattach themselves to the nervous system.

Until now, all damage to the nerve cells of the central nervous system - the brain and spinal cord – had been considered irreparable.

Mr Rodda said the lack of repair, or regrowth is due mainly to the toxic environment left behind after nerve death.

“Nerve cells are sensitive, and will only grow in the most supportive of environments,” Mr Rodda said.

“After injury, new cells cannot normally penetrate into the empty space left after mass cell death. Cells clump at the edges, forming an impenetrable barrier. This leaves the centre of the wound as a lesion, which contains chemicals that kill growing nerves.”

Mr Rodda said the new biomaterial works by providing a temporary scaffold on which new cells can grow and penetrate the lesion.

Significantly, it was the helper cells, known as astrocytes, which were the first to move into the implanted gel. These cells secrete beneficial chemicals, which may have helped create an environment in which the delicate nerve cells can survive.

Mr Rodda’s study is part of a worldwide effort to encourage nerve regeneration in the brain and spinal cord. It builds on previous work at Monash University to understand and control nerve growth using biomaterials.

New drug heals lungs

FLINDERS UNIVERSITY

A new drug to treat potentially fatal lung injuries caused by ventilators in hospital intensive care units is being developed by Flinders University researchers.

Ms Alison Elder, a PhD candidate in the Department of Critical Care Medicine, and her colleagues have trialled feG, a new anti-inflammatory drug that successfully treats bacterial pneumonia and acute pancreatitis, in models of lung injury in rats.

They found the drug may be able to both prevent and effectively treat ventilator-induced lung injury.

“Ventilators are essential to keep people breathing in intensive care but can also cause deadly lung damage by forcefully stretching the delicate tissues of the lung,” Ms Elder said.

“By significantly reducing lung damage and improving respiratory function, this drug could reduce patient mortality in the intensive care unit,” she said.

Stretching of the lung tissue triggers our immune system to release chemicals that cause inflammation. This can result in further tissue damage, impaired oxygen exchange, and fluid accumulation in the lung, leading to death.

“The drug works in three ways: it decreases the infiltration of the inflammatory cells into the lung; it decreases their activation; and it encourages resolution of the injury within the lung,” Ms Elder said.

Mortality rates for patients with acute lung injury increase from 24 per cent for patients 15-19 years old up to 60 per cent for patients 85 years and older, and it is also a significant financial burden for the health system.

The drug, which is based on a natural substance found in the salivary glands of rats, is currently being tested for treating asthma in Phase 1 trials by collaborators in Canada.

“Since patient safety testing has already begun in the asthma study, we are hoping to be in a position to start clinical trials here in Adelaide within the next few years.”

‘Homeless’ before mental issues

RMIT UNIVERSITY

RMIT University researchers have challenged widely-held beliefs about the connections between homelessness and mental illness in a groundbreaking study.

The research paper by Dr Guy Johnson and Professor Chris Chamberlain will be published in the Australian Journal of Social Issues (Autumn, 2011).

Dr Johnson, a Senior Research Fellow with the Australian Housing and Urban Research Institute (AHURI) at RMIT, and Professor Chamberlain, Director of the Centre for Applied Social Research, used information from a study of 4,291 homeless people in their research.

They found only 15 per cent had mental health issues before becoming homeless, while 16 per cent of the sample developed mental health problems after becoming homeless.

Dr Johnson said the findings challenged the community perception that mental illness was the primary cause of homelessness.

"Our research shows the vast majority of people do not have mental health problems before becoming homeless," he said.

"Homelessness does cause mental health issues, particularly anxiety and depression, and is a serious problem for a significant minority of homeless people.

"But the claim that most homeless people are mentally ill - or that mental illness is the primary cause of homelessness - sends the wrong message to policy makers about the services that are needed to help people out of homelessness."

The Australian Research Council-funded study, which used case records of 4,291 people using two homelessness services in inner-Melbourne, also found:

78 per cent of those who developed mental health issues after becoming homeless were 24 or younger when homelessness first occurred
63 per cent of the young people who developed mental health problems after becoming homeless also had substance abuse issues
80 per cent of the sample had been homeless for one year or longer and 50 per cent had been homeless for two years or more

Dr Johnson said focusing too heavily on mental health deflected attention from the more pervasive structural causes of homelessness, such as family breakdown, insufficient income and a lack of affordable housing.

"For homeless people directly affected by these structural factors, the solution lies outside the medical arena – and research indicates that providing housing to homeless people before treating their mental health issues is actually a more effective approach," he said.

‘Dim light’ finds eye disease

QUEENSLAND UNIVERSITY OF TECHNOLOGY

The researchers hope that this test will be used by ophthalmologists and optometrists to identify patients with a high genetic risk of developing AMD.

Image: nyul/iStockphoto

The leading cause of blindness in Australia, age-related macular degeneration (AMD), may be detected in healthy people at risk of developing the disease thanks to the discovery of a technique for early detection by researchers at Queensland University of Technology (QUT).

Using standard clinical techniques, the detection of AMD has previously not been possible in the disease's early, or "subclinical", stages. Practitioners tend to diagnose AMD once small changes become visible at the back of a patient's eye. However, degeneration begins many years before these clinical signs appear.

During a two-year research project, eye specialist Dr Beatrix Feigl from QUT's Institute of Health and Biomedical Innovation (IHBI) used a "dim light vision" test which was very sensitive to early changes in a person's vision.

"We can detect subclinical visual impairment in healthy participants genetically at risk for AMD," she said.

"In the future we hope this test might be utilised by ophthalmologists and optometrists to identify patients with a high genetic risk of developing AMD but without any clinical signs of the disease. This would enable specialists to advise patients on lifestyle changes which may delay disease onset and reduce its severity."

Dr Feigl said that genetic pre-disposition accounted for around half the cases of AMD. However, lifestyle risk factors for AMD, which could be controlled by a patient, included poor diet, lack of exercise and smoking.

"We know that lifestyle changes can decrease a person's chance of getting worse forms of the disease," she said.

The number of people who could potentially benefit from this research is huge.

"One in seven Australians over 50 is affected by this disease," Dr Feigl said.

The next phase of Dr Feigl's research will be a longitudinal study, following up with people who took part in the study who were shown to have early changes to their vision.

"We will follow them up and see if their vision deteriorates over time," she said.

It is hoped that this second stage of the research will prove that the subclinical vision impairment has been an accurate predictor of AMD.

Dr Feigl said that people could currently be gene tested, and lifestyle risk factors could be analysed. However, neither of these predictors alone was entirely prognostic. A clinical vision test was needed to allow a rigorous assessment of the role of both genes and lifestyle on AMD development.

வெறும் நூறு ரூபாயில் புற்று நோயை முற்றிலும் அழிக்க , வராமல் தடுக்க ஒரு சிறந்த கை மருந்து !

ரொம்ப வேடிக்கைக்காக சொல்வது உண்டு. உலகத்திலேயே ரொம்ப ஈசியான விஷயம், சிகரெட் ஸ்மோக் பண்றதை விடுறதுதான் மச்சி!. நான் எத்தனை தடவை விட்டுருக்கேன் தெரியுமா?

http://t2.gstatic.com/images?q=tbn:ANd9GcSM6n2eVzbJ1m3Odk89F9hz6T3vMO6MFPSWRsf7y9Z0TjbkAloERw

"மச்சி, சரக்கு விட சொல்றா.. விட்டுரலாம். ஆனா , சிகரெட் விடுவது ரொம்ப ரொம்ப கஷ்டம்பா"... இது , புகை பழக்கம் உள்ள எல்லோரும் சொல்ற டயலாக்.
நிக்கோடின் பவர் அந்த மாதிரி .அப்படி சிகெரெட் பிடிப்பவர்களில் 10 க்கு 6 பேர்

புற்று நோயால் பாதிக்கப் படுகிறார்களாம். சொந்த செலவிலேயே சூனியம் வைக்கறதுக்கு சமம். சொன்னா யார் கேட்கப்போறா !?

புற்று நோய் வந்து விட்டது என்றாலே சகல சப்த நாடிகளும் ஒடுங்கிப்போய் தளர்ந்து விடுவார்கள். அருகில் இருந்து பார்த்தவர்களுக்குத் தான் தெரியும் , சிங்கம் போலே சிலுப்பிக் கொண்டு இருந்த பலரை , வேரோடு சாய்த்து விடும் தன்மை. இந்த புற்று நோய்க்கு உண்டு. இப்போது ஓரளவுக்கு மெடிக்கல் உலகம் சில மருந்துகளை கண்டுபிடித்து , குணப் படுத்த நடவடிக்கை எடுத்தாலும், பணம் இருப்பவர்கள் மட்டுமே அந்த சிகிச்சை மேற்கொள்ள முடியும். ஆனால் அந்த வேதனை , ரணம் உயிரை விட்டு விடுவதே மேல் என்றே தோன்றி விடும்.

எனக்கு தெரிந்து , மிக நெருக்கமான வட்டத்தில் - மூன்று பேரை , அவர்கள் ஒட்டு மொத்த சொத்தையும் செலவழித்துப் பார்த்தும், உயிரையே காவு வாங்கி விட்டது.

அதை விட கொடூரமாக வேறு எந்த நோயின் வீரியத்தையும் கண் முன்னே நான் பார்த்ததில்லை.

அப்படிப்பட்ட புற்று நோயை , படிப்படியாக முற்றிலும் குணப்படுத்த ஒரு எளிய வைத்தியம் இது.

இந்த சிகிச்சையை கண்டுபிடித்தவர் பிரேசில் நாட்டில் பிறந்தவரும் சிறந்த மருத்துவரும் பாதிரியாருமாகிய Fr ரோமனோ சகோ (Fr Romano Zago) என்பவர்.

இவர் கண்டு பிடித்த இம்மருந்தை புற்று நோயால் மிக கடுமையாக பாதிக்கப் பட்டவர்கள்கூட உபயோகித்து குணமடைந்துள்ளனர். .

இனி இம்மருந்தை எப்படி தயாரிப்பது என்பதை பார்ப்போம் .இதில் பயன்படுத்தப்படும் மூலிகை எங்கும் எளிதாக கிடைக்கும் சோற்று கற்றாழை ஆகும் .

சோற்று கற்றாழை 400 கிராம்
சுத்தமான தேன் 500 கிராம்
whisky(or)brandy 50 மில்லி

தயாரிப்பு முறை

சோற்றுக் கற்றாழையை எடுத்து பக்கவாட்டில் உள்ள முட்களை நீக்கி கொள்ள வேண்டும்

தோலை நீக்கிவிடக்கூடாது

தோலை சுத்தமான துணியினால் துடைத்துக் கொள்ளவேண்டும்

அடுத்த படியாக எவ்வளவு முடியுமோ அவ்வளவு சிறியதாக கற்றாழையை நறுக்கிக் கொள்ளவேண்டும்

நறுக்கப்பட்ட துண்டுகளை ஒரு பாத்திரத்தில் கொட்டி தேன் மற்றும் whisky (or) brandy யுடன் சேர்த்து ஒரு கரண்டியால் நன்றாக கலக்க வேண்டும்

இப்போது மருந்து தயாராகி விட்டது

மருந்தை உட்கொள்ளும் விதம்

இம்மருந்தை தினமும் மூன்று வேளை உணவு அருந்துவதற்கு 30 நிமிடத்திற்கு முன்பு 15 ml வீதம் உண்ணவேண்டும் .ஒவ்வொரு முறை பயன்படுத்தும்போதும் மருந்தை நன்றாக குலுக்கிக் கொள்ளவேண்டும. மேலே சொன்ன அளவில் செய்தால் பத்து நாட்களுக்கு இந்த மருந்து வரும். மருந்து தீர்ந்தவுடன் 10 நாள் கழித்து மீண்டும் தயாரித்து உண்ணவேண்டும. பத்து நாட்களுக்கு மேல் மருந்தை storage செய்ய கூடாது.

இடையிடையே மருத்துவ பரிசோதனை செய்து கொண்டு நோய் நன்கு குணமாகும் வரை மருந்தை உட்கொள்ளவேண்டும் .சிலருக்கு மிக குறுகிய காலத்திலேயே இதன் மூலம் நிவாரணம் கிடைத்துள்ளது .

இது மிகவும் எளிதான சக்தி மிகுந்த மருந்து ஆகும் . மருந்தை குளிர்சாதன பெட்டியிலோ அல்லது அதிக வெப்பம் இல்லாத இடங்களிலோ காற்று புகாத பாட்டிலில் வைத்திருப்பது நல்லது .

உங்களால் முடிந்தவரை உங்கள் நட்பு வட்டாரத்தில் இதை தெரியப்படுத்துங்கள். யாரோ ஒருவருக்கு இது மிக தேவையானதாக இருக்க கூடும்... ! சிகரெட் பிடிக்கும் அனைவரும் உடனடியாக , புகை பழக்கத்தை நிறுத்தி , இந்த மருந்தை உட்கொள்ள ஆரம்பித்தல் நல்லது.

ஒரே ஒரு நிமிஷம் , உங்களுக்கு புற்று நோய் வந்துடுச்சுனு டாக்டர் சொல்றதா நினைச்சுக்கோங்க.. கண் முன்னாலே உங்க மனைவி, குழந்தைகள், வயசான அப்பா , அம்மா எல்லோரும், நீங்க இல்லாம - கஷ்டப்படப் போறதை நினைச்சுப் பாருங்க... அந்த கருமத்தை , இதுக்கு மேலே தொடுவீங்க !?

நாம மனசு வைச்ச எல்லாம் முடியும் சார்! எத்தனையோ தடவை விட்டுப் பார்த்தாச்சு.. இன்னும் ஒரே ஒரு தடவை, கடைசியா விட்டுப் பாருங்களேன்!